In last trading session, Ensysce Biosciences Inc (NASDAQ:ENSC) saw 0.55 million shares changing hands with its beta currently measuring 0.61. Company’s recent per share price level of $0.53 trading at $0.03 or 5.95% at ring of the bell on the day assigns it a market valuation of $10.39M. That closing price of ENSC’s stock is at a discount of -288.68% from its 52-week high price of $2.06 and is indicating a premium of 73.58% from its 52-week low price of $0.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.31 million shares which gives us an average trading volume of 26.35 million if we extend that period to 3-months.
For Ensysce Biosciences Inc (ENSC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.13 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ensysce Biosciences Inc (NASDAQ:ENSC) trade information
Upright in the green during last session for gaining 5.95%, in the last five days ENSC remained trading in the red while hitting it’s week-highest on Friday, 11/22/24 when the stock touched $0.53 price level, adding 5.36% to its value on the day. Ensysce Biosciences Inc’s shares saw a change of -49.91% in year-to-date performance and have moved -10.36% in past 5-day. Ensysce Biosciences Inc (NASDAQ:ENSC) showed a performance of -16.81% in past 30-days. Number of shares sold short was 6.35 million shares which calculate 0.12 days to cover the short interests.
Ensysce Biosciences Inc (ENSC) estimates and forecasts
Statistics highlight that Ensysce Biosciences Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -7.65% of value to its shares in past 6 months, showing an annual growth rate of 82.30% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 86.06% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 245k for the same. Company posted 515.03k and 305.72k of sales in current and next quarters respectively a year earlier.
Ensysce Biosciences Inc (NASDAQ:ENSC)’s Major holders
Insiders are in possession of 1.17% of company’s total shares while institution are holding 22.26 percent of that, with stock having share float percentage of 22.53%. Investors also watch the number of corporate investors in a company very closely, which is 22.26% institutions for Ensysce Biosciences Inc that are currently holding shares of the company. PLANTE MORAN FINANCIAL ADVISORS, LLC is the top institutional holder at ENSC for having 20.0 shares of worth $10.0. And as of 2024-06-30, it was holding 0.0004 of the company’s outstanding shares.
On the other hand, Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 43.23 shares of worth $21352.0 or 0.22% of the total outstanding shares. The later fund manager was in possession of 18.18 shares on Jun 30, 2024 , making its stake of worth around $8976.0 in the company or a holder of 0.09% of company’s stock.
